AR081889A1 - Forma cristalina de cloruro de glicopirronio - Google Patents

Forma cristalina de cloruro de glicopirronio

Info

Publication number
AR081889A1
AR081889A1 ARP110102059A ARP110102059A AR081889A1 AR 081889 A1 AR081889 A1 AR 081889A1 AR P110102059 A ARP110102059 A AR P110102059A AR P110102059 A ARP110102059 A AR P110102059A AR 081889 A1 AR081889 A1 AR 081889A1
Authority
AR
Argentina
Prior art keywords
chloride
glicopirron
crystal form
crystalline
hydroxyphenylacetyl
Prior art date
Application number
ARP110102059A
Other languages
English (en)
Inventor
Fausto Pivetti
Monica Bocchi
Ernesto Landonio
Enrico Vigano
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR081889A1 publication Critical patent/AR081889A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Proceso de preparación, composición farmacéutica y uso para tratar enfermedades respiratorias.Reivindicación 1: Cloruro de (3R,2’S)- y (3S,2’R)-[(ciclopentil-hidroxifenilacetil)oxi]-1,1-dimetilpirrolidinio cristalino (cloruro de treo glicopirronio) monohidrato, caracterizado porque tiene los siguientes picos XRPD característicos a 2q en grados angulares usando radiación Cu-Ka (precisión ± 0,1º): 5,40; 10,65; 11,32; 12,46; 14,88; 17,16; 18,47; 18,69; 19,24; 22,08; 22,74; 25,40; 25,54; 26,57 y 28,40.
ARP110102059A 2010-06-14 2011-06-13 Forma cristalina de cloruro de glicopirronio AR081889A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10165786 2010-06-14

Publications (1)

Publication Number Publication Date
AR081889A1 true AR081889A1 (es) 2012-10-24

Family

ID=42751657

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102059A AR081889A1 (es) 2010-06-14 2011-06-13 Forma cristalina de cloruro de glicopirronio

Country Status (11)

Country Link
US (1) US9174937B2 (es)
EP (1) EP2580195B1 (es)
KR (1) KR101736529B1 (es)
CN (1) CN102939280B (es)
AR (1) AR081889A1 (es)
BR (1) BR112012031451A2 (es)
CA (1) CA2802584C (es)
ES (1) ES2528957T3 (es)
HK (1) HK1177200A1 (es)
RU (1) RU2569852C2 (es)
WO (1) WO2011157387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP3293176B1 (en) 2013-10-22 2020-12-02 Chiesi Farmaceutici S.p.A. Crystal form of a pde4 inhibitor
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
RU2238936C2 (ru) * 1996-11-11 2004-10-27 Кристиан Р. НОЕ Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
AT412088B (de) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
US20070185067A1 (en) * 2004-02-27 2007-08-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
KR101290893B1 (ko) * 2009-04-09 2013-07-29 노파르티스 아게 피롤리디늄 염의 제조 방법

Also Published As

Publication number Publication date
EP2580195A1 (en) 2013-04-17
US20110305645A1 (en) 2011-12-15
KR101736529B1 (ko) 2017-05-17
CA2802584A1 (en) 2011-12-22
HK1177200A1 (en) 2013-08-16
RU2012154006A (ru) 2014-07-20
US9174937B2 (en) 2015-11-03
EP2580195B1 (en) 2014-12-03
ES2528957T3 (es) 2015-02-13
CA2802584C (en) 2018-08-21
CN102939280B (zh) 2014-11-19
BR112012031451A2 (pt) 2016-12-06
CN102939280A (zh) 2013-02-20
KR20130119844A (ko) 2013-11-01
RU2569852C2 (ru) 2015-11-27
WO2011157387A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
PH12015500719A1 (en) Gdf-8-inhibitors
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
BR112012029405A8 (pt) compostos macrocíclicos como inibidores de trk quinase
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
EA201492125A1 (ru) НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
EA201101507A1 (ru) Способы лечения солидных опухолей
MX2014012695A (es) Derivados de isoindolona.
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MY172924A (en) Neprilysin inhibitors
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
HK1138262A1 (en) Novel phosphodiesterase inhibitors
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
WO2013004995A8 (en) Pyrimidinone compounds and their use
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
MY145795A (en) Pyrazoline compounds
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
MX2013012588A (es) Inhibidores de cinasa.
MX340300B (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3

Legal Events

Date Code Title Description
FB Suspension of granting procedure